New Study Reveals Plasma Biomarkers Highlight Distinct Biological Responses to Lecanemab in Alzheimer Disease

As anti-amyloid therapies become part of routine care for Alzheimer disease (AD), researchers are investigating how blood-based biomarkers can help characterize biological responses to treatment and explain differences in clinical outcomes. Although lecanemab reduces amyloid burden and slows cognitive decline, patients do not experience the same degree of clinical benefit. Understanding how biomarkers change during […] The post New Study Reveals Plasma Biomarkers Highlight Distinct Biological Responses to Lecanemab in Alzheimer Disease appeared first on Alamar Biosciences .